ME01924B
(me)
|
2010-07-22 |
2015-05-20 |
Gilead Sciences Inc |
Metode i jedinjenja za lečenje infekcija izazvanih Paramyxoviridae virusom
|
BR112014015197A2
(pt)
|
2011-12-21 |
2017-06-13 |
Novira Therapeutics Inc |
agentes antivirais de hepatite b
|
US20130267517A1
(en)
|
2012-03-31 |
2013-10-10 |
Hoffmann-La Roche Inc. |
Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
MX2015002511A
(es)
*
|
2012-08-24 |
2016-03-08 |
Sunshine Lake Pharma Co Ltd |
Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos.
|
CR20210079A
(es)
|
2012-08-28 |
2021-06-10 |
Janssen Sciences Ireland Uc |
Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
|
EA029174B1
(ru)
|
2012-09-10 |
2018-02-28 |
Рита Фармасьютикалз, Инк. |
C17-алкандиильные и алкендиильные производные олеаноловой кислоты и способы их применения
|
EA027194B1
(ru)
|
2013-02-28 |
2017-06-30 |
Янссен Сайенсиз Айрлэнд Юси |
Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
|
WO2014165128A2
(en)
|
2013-03-12 |
2014-10-09 |
Novira Therapeutics, Inc. |
Hepatitis b antiviral agents
|
JP6419155B2
(ja)
|
2013-04-03 |
2018-11-07 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
N−フェニル−カルボキサミド誘導体およびb型肝炎を治療するための医薬品としてのその使用
|
JO3603B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
JP6533217B2
(ja)
*
|
2013-05-17 |
2019-06-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
B型肝炎ウイルス感染症の治療および予防のための6−架橋ヘテロアリールジヒドロピリミジン類
|
AP2015008968A0
(en)
|
2013-07-25 |
2015-12-31 |
Janssen Sciences Ireland Uc |
Glyoxamide substituted pyrrolamide derivatives andthe use thereof as medicaments for the treatment of hepatitis b
|
ES2655518T3
(es)
|
2013-10-23 |
2018-02-20 |
Janssen Sciences Ireland Uc |
Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
|
MX2016006564A
(es)
*
|
2013-11-19 |
2017-09-12 |
Sunshine Lake Pharma Co Ltd |
Compuestos dihidropirimidina y su aplicacion en productos farmaceuticos.
|
KR102284938B1
(ko)
*
|
2013-11-27 |
2021-08-02 |
선샤인 레이크 파르마 컴퍼니 리미티드 |
다이하이드로피리미딘 유도체 및 이의 중간산물의 제조 방법
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
US9181288B2
(en)
|
2014-01-16 |
2015-11-10 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
MX2016009449A
(es)
|
2014-02-05 |
2016-10-13 |
Novira Therapeutics Inc |
Terapia de combinacion para el tratamiento de infecciones por virus de la hepatitis b (vhb).
|
JP6495929B2
(ja)
|
2014-02-06 |
2019-04-03 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
スルファモイルピロールアミド誘導体およびb型肝炎の治療のための医薬としてのその使用
|
US9796741B2
(en)
|
2014-02-25 |
2017-10-24 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
|
AU2015229174B2
(en)
|
2014-03-13 |
2019-04-11 |
Assembly Biosciences, Inc. |
Hepatitis B core protein allosteric modulators
|
US9400280B2
(en)
|
2014-03-27 |
2016-07-26 |
Novira Therapeutics, Inc. |
Piperidine derivatives and methods of treating hepatitis B infections
|
CN104945395B
(zh)
*
|
2014-03-28 |
2018-01-23 |
广东东阳光药业有限公司 |
二氢嘧啶类化合物及其在药物中的应用
|
WO2015172128A1
(en)
*
|
2014-05-09 |
2015-11-12 |
Indiana University Research And Technology Corporation |
Methods and compositions for treating hepatitis b virus infections
|
WO2016012470A1
(en)
*
|
2014-07-25 |
2016-01-28 |
F. Hoffmann-La Roche Ag |
New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
|
AR101319A1
(es)
*
|
2014-07-31 |
2016-12-07 |
Hoffmann La Roche |
Resolución quiral de los ésteres del ácido 4-aril-2-tiazol-2-il-1,4-dihidropirimidin-5-carboxílico
|
CN104327006A
(zh)
*
|
2014-10-19 |
2015-02-04 |
湖南华腾制药有限公司 |
一种5-乙基-4-甲酰胺基恶唑的制备方法
|
TWI698444B
(zh)
|
2014-10-29 |
2020-07-11 |
美商基利科學股份有限公司 |
製備核糖苷的方法
|
WO2016102438A1
(en)
*
|
2014-12-23 |
2016-06-30 |
F. Hoffmann-La Roche Ag |
Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues
|
JP2018502604A
(ja)
|
2015-01-27 |
2018-02-01 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
組換えHBV cccDNA、その作製方法およびその使用
|
CA2970838A1
(en)
*
|
2015-02-07 |
2016-08-11 |
Sunshine Lake Pharma Co., Ltd. |
Complexes and salts of dihydropyrimidine derivatives and their application in pharmaceuticals
|
PL3097102T3
(pl)
|
2015-03-04 |
2018-04-30 |
Gilead Sciences Inc |
Związki 4,6-diamino-pirydo[3,2-d]pirymidyny modulujące działanie receptora toll-podobnego
|
SI3270915T1
(sl)
*
|
2015-03-16 |
2020-07-31 |
F. Hoffmann-La Roche Ag |
Kombinirano zdravljenje z agonistom TLR7 in zaviralcem sestavljanja kapside HBV
|
EP3271019A1
(en)
|
2015-03-19 |
2018-01-24 |
Novira Therapeutics Inc. |
Azocane and azonane derivatives and methods of treating hepatitis b infections
|
US10442788B2
(en)
|
2015-04-01 |
2019-10-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
CA2981856A1
(en)
*
|
2015-04-14 |
2016-10-20 |
Gilead Sciences, Inc. |
Methods of treating hepatitis b virus
|
US10738035B2
(en)
|
2015-05-13 |
2020-08-11 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
WO2016202721A1
(en)
|
2015-06-16 |
2016-12-22 |
F. Hoffmann-La Roche Ag |
Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
US10179131B2
(en)
|
2015-07-13 |
2019-01-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
US10301255B2
(en)
|
2015-07-22 |
2019-05-28 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
WO2017035351A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of medical disorders
|
MA42684A
(fr)
|
2015-08-26 |
2018-07-04 |
Gilead Sciences Inc |
Modulateurs deutérés du récepteur toll
|
WO2017035401A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amide compounds for treatment of immune and inflammatory disorders
|
WO2017035355A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Ether compounds for treatment of medical disorders
|
EP3340983B1
(en)
|
2015-08-26 |
2023-10-04 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
|
WO2017035357A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Phosphonate compounds for treatment of medical disorders
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
WO2017035408A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Compounds for treatment of immune and inflammatory disorders
|
AR105808A1
(es)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos de amida para el tratamiento de trastornos médicos
|
WO2017035405A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of immune and inflammatory disorders
|
AR105809A1
(es)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos para el tratamiento de trastornos médicos
|
WO2017035361A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Disubstituted compounds for the treatment of medical disorders
|
TWI730985B
(zh)
|
2015-09-15 |
2021-06-21 |
美商艾森伯利生物科學公司 |
B型肝炎核心蛋白質調節劑
|
EP3349758B1
(en)
|
2015-09-16 |
2022-04-06 |
Gilead Sciences, Inc. |
Methods for treating arenaviridae virus infections
|
AR106192A1
(es)
|
2015-09-29 |
2017-12-20 |
Novira Therapeutics Inc |
Formas cristalinas de un agente antiviral contra la hepatitis b
|
WO2017064156A1
(en)
|
2015-10-16 |
2017-04-20 |
F. Hoffmann-La Roche Ag |
Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
KR102181168B1
(ko)
*
|
2015-11-03 |
2020-11-23 |
에프. 호프만-라 로슈 아게 |
Hbv 캡시드 조립 억제제와 인터페론의 조합 치료
|
WO2017108630A1
(en)
*
|
2015-12-21 |
2017-06-29 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
|
US10280175B2
(en)
|
2016-02-02 |
2019-05-07 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
AR107633A1
(es)
|
2016-02-19 |
2018-05-16 |
Hoffmann La Roche |
Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico
|
KR102398439B1
(ko)
|
2016-03-07 |
2022-05-16 |
이난타 파마슈티칼스, 인코포레이티드 |
B형 간염 항바이러스제
|
CN107200733A
(zh)
*
|
2016-03-18 |
2017-09-26 |
广东东阳光药业有限公司 |
二氢嘧啶衍生物的晶型及其在药物中的应用
|
MX2018012557A
(es)
|
2016-04-15 |
2019-07-04 |
Janssen Sciences Ireland Uc |
Combinaciones y métodos que comprenden un inhibidor del ensamblaje de la cápside.
|
SG11201809893WA
(en)
|
2016-05-27 |
2018-12-28 |
Gilead Sciences Inc |
Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
KR20190027814A
(ko)
|
2016-06-10 |
2019-03-15 |
이난타 파마슈티칼스, 인코포레이티드 |
B형 간염 항바이러스제
|
CN109689059A
(zh)
*
|
2016-08-24 |
2019-04-26 |
豪夫迈·罗氏有限公司 |
Hbv衣壳组装抑制剂和核苷或核苷酸类似物的组合疗法
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
EP3507288B1
(en)
|
2016-09-02 |
2020-08-26 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
EP3507276B1
(en)
|
2016-09-02 |
2021-11-03 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
CN109715214B
(zh)
|
2016-09-13 |
2022-03-04 |
豪夫迈·罗氏有限公司 |
Tlr7激动剂和hbv衣壳组装抑制剂的组合治疗
|
CA3037151A1
(en)
|
2016-09-15 |
2018-03-22 |
Assembly Biosciences, Inc. |
Hepatitis b core protein modulators
|
CA3040143A1
(en)
|
2016-10-14 |
2018-04-19 |
Precision Biosciences, Inc. |
Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
|
MX2019005119A
(es)
|
2016-11-18 |
2019-06-20 |
Sichuan Kelun Biotech Biopharmaceutical Co Ltd |
Compuesto de dihidropirimidina y metodo de preparacion y uso del mismo.
|
US11166954B2
(en)
|
2016-11-18 |
2021-11-09 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Dihydropyrimidine compound and preparation method and use thereof
|
TWI820984B
(zh)
|
2017-01-31 |
2023-11-01 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
WO2018160891A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceutical, Inc. |
Pharmaceutical compounds for treatment of medical disorders
|
WO2018160889A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
|
ES2933513T3
(es)
|
2017-03-01 |
2023-02-09 |
Achillion Pharmaceuticals Inc |
Compuestos macrocíclicos para el tratamiento de trastornos médicos
|
JP2020511436A
(ja)
|
2017-03-02 |
2020-04-16 |
アッセンブリー バイオサイエンシズ,インコーポレイテッド |
環状スルファミド化合物およびその使用方法
|
KR102460968B1
(ko)
*
|
2017-03-14 |
2022-11-01 |
길리애드 사이언시즈, 인코포레이티드 |
고양이 코로나바이러스 감염의 치료 방법
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
CA3059777C
(en)
|
2017-05-01 |
2023-02-21 |
Gilead Sciences, Inc. |
Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
|
WO2019001420A1
(en)
|
2017-06-27 |
2019-01-03 |
Janssen Pharmaceutica Nv |
HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING INFECTIONS WITH HEPATITIS B VIRUS
|
EP3651734A1
(en)
|
2017-07-11 |
2020-05-20 |
Gilead Sciences, Inc. |
Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
|
US11040033B2
(en)
|
2017-08-22 |
2021-06-22 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
MX2020002191A
(es)
|
2017-08-28 |
2020-10-05 |
Enanta Pharm Inc |
Agentes antivirales contra la hepatitis b.
|
WO2019113173A1
(en)
|
2017-12-06 |
2019-06-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
TW201936192A
(zh)
|
2017-12-06 |
2019-09-16 |
美商因那塔製藥公司 |
B 型肝炎抗病毒試劑
|
CN111566120B
(zh)
|
2017-12-20 |
2023-09-29 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
|
WO2019123339A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
US11447489B2
(en)
|
2017-12-28 |
2022-09-20 |
Hoffmann-La Roche Inc. |
Dihydropyrimidinylthiazole for the treatment and prophylaxis of hepatitis B virus infection
|
WO2019143902A2
(en)
|
2018-01-22 |
2019-07-25 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
TWI707849B
(zh)
|
2018-02-13 |
2020-10-21 |
美商基利科學股份有限公司 |
Pd‐1/pd‐l1抑制劑
|
PL3759109T3
(pl)
|
2018-02-26 |
2024-03-04 |
Gilead Sciences, Inc. |
Podstawione związki pirolizyny jako inhibitory replikacji hbv
|
JP2021515769A
(ja)
|
2018-03-14 |
2021-06-24 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
カプシド集合調節剤の投薬レジメン
|
US10729688B2
(en)
|
2018-03-29 |
2020-08-04 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
EP3774883A1
(en)
|
2018-04-05 |
2021-02-17 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
2,2,─環二核苷酸
|
JP7296398B2
(ja)
|
2018-04-06 |
2023-06-22 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. |
3’3’-環状ジヌクレオチド
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
CN108218809B
(zh)
*
|
2018-04-14 |
2021-03-26 |
宁夏法安德药业有限公司 |
一种医药中间体2-氨基噻唑-4-甲酸乙酯的合成方法
|
TWI712412B
(zh)
|
2018-04-19 |
2020-12-11 |
美商基利科學股份有限公司 |
Pd‐1/pd‐l1抑制劑
|
TW202014193A
(zh)
|
2018-05-03 |
2020-04-16 |
捷克科學院有機化學與生物化學研究所 |
包含碳環核苷酸之2’3’-環二核苷酸
|
EP3817818A1
(en)
|
2018-07-06 |
2021-05-12 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
US11098027B2
(en)
|
2018-07-06 |
2021-08-24 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
WO2020014643A1
(en)
|
2018-07-13 |
2020-01-16 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
US11053235B2
(en)
|
2018-08-09 |
2021-07-06 |
Janssen Sciences Ireland Unlimited Company |
Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
|
CA3111810A1
(en)
|
2018-09-06 |
2020-03-12 |
Achillion Pharmaceuticals, Inc. |
Morphic forms of dancopan
|
US11814391B2
(en)
|
2018-09-06 |
2023-11-14 |
Achillion Pharmaceuticals, Inc. |
Macrocyclic compounds for the treatment of medical disorders
|
JP2022500466A
(ja)
|
2018-09-21 |
2022-01-04 |
エナンタ ファーマシューティカルズ インコーポレイテッド |
抗ウイルス剤としての官能化複素環
|
KR20210093855A
(ko)
|
2018-09-25 |
2021-07-28 |
아칠리온 파르마세우티칼스 인코포레이티드 |
보체 인자 d 억제제의 형태체 형태
|
JP2022508953A
(ja)
|
2018-10-22 |
2022-01-19 |
アッセンブリー バイオサイエンシズ,インコーポレイテッド |
Hbvの処置のための5員のヘテロアリールカルボキサミド化合物
|
CN112955435A
(zh)
|
2018-10-24 |
2021-06-11 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
EP3873488A4
(en)
|
2018-10-31 |
2022-08-03 |
The University of Sydney |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRUS INFECTION
|
MX2021005047A
(es)
|
2018-10-31 |
2021-09-08 |
Gilead Sciences Inc |
Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
|
US11198693B2
(en)
|
2018-11-21 |
2021-12-14 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
TW202035412A
(zh)
*
|
2018-12-20 |
2020-10-01 |
比利時商健生藥品公司 |
雜芳基二氫嘧啶衍生物和治療b型肝炎感染之方法
|
EP3927698A1
(en)
|
2019-02-22 |
2021-12-29 |
Janssen Sciences Ireland Unlimited Company |
Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
|
DK3934757T3
(da)
|
2019-03-07 |
2023-04-17 |
Inst Of Organic Chemistry And Biochemistry Ascr V V I |
2'3'-cykliske dinukleotider og prodrugs deraf
|
US20220143061A1
(en)
|
2019-03-07 |
2022-05-12 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
EP3935065A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
AU2020249331A1
(en)
|
2019-03-25 |
2021-09-23 |
F. Hoffmann-La Roche Ag |
Solid forms of a compound of HBV core protein allosteric modifier
|
US20230227446A9
(en)
|
2019-04-10 |
2023-07-20 |
Nanjing Zhengxiang Pharmaceuticals Co., Ltd. |
Phosphatidylinositol 3-kinase inhibitors
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
CA3132554A1
(en)
|
2019-05-06 |
2020-11-12 |
Bart Rudolf Romanie Kesteleyn |
Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
CA3140103A1
(en)
|
2019-05-24 |
2020-12-03 |
Assembly Biosciences, Inc. |
Pharmaceutical compositions for the treatment of hbv
|
US11236111B2
(en)
|
2019-06-03 |
2022-02-01 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
WO2020247561A1
(en)
|
2019-06-04 |
2020-12-10 |
Enanta Pharmaceuticals, Inc, |
Hepatitis b antiviral agents
|
US11472808B2
(en)
|
2019-06-04 |
2022-10-18 |
Enanta Pharmaceuticals, Inc. |
Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
|
EP3980406A4
(en)
*
|
2019-06-06 |
2023-06-28 |
Aligos Therapeutics, Inc. |
Heterocyclic compounds
|
WO2020255038A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
BR112021026376A2
(pt)
|
2019-06-25 |
2022-05-10 |
Gilead Sciences Inc |
Proteínas de fusão flt3l-fc e métodos de uso
|
WO2021007488A1
(en)
|
2019-07-11 |
2021-01-14 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
CA3146997A1
(en)
*
|
2019-07-31 |
2021-02-04 |
Janssen Sciences Ireland Unlimited Company |
Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
|
EP4003987A4
(en)
*
|
2019-07-31 |
2023-07-26 |
Janssen Sciences Ireland Unlimited Company |
DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES
|
KR20220045189A
(ko)
|
2019-08-12 |
2022-04-12 |
데시페라 파마슈티칼스, 엘엘씨. |
위장관 기질 종양을 치료하는 방법
|
TW202122082A
(zh)
|
2019-08-12 |
2021-06-16 |
美商迪賽孚爾製藥有限公司 |
治療胃腸道基質瘤方法
|
WO2021034804A1
(en)
|
2019-08-19 |
2021-02-25 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
US11236108B2
(en)
|
2019-09-17 |
2022-02-01 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
PE20221111A1
(es)
|
2019-09-30 |
2022-07-11 |
Gilead Sciences Inc |
Vacunas para vhb y metodos de tratamiento de vhb
|
KR102264881B1
(ko)
|
2019-11-08 |
2021-06-14 |
중앙대학교 산학협력단 |
듀얼 msm 소자를 구비한 휴대단말기 카메라용 액추에이터 및 이를 구비한 휴대단말기용 카메라모듈
|
WO2021113765A1
(en)
|
2019-12-06 |
2021-06-10 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
KR20220131918A
(ko)
|
2019-12-24 |
2022-09-29 |
카나 바이오사이언스, 인코포레이션 |
다이아실글리세롤 키나제 조절 화합물
|
CN115243681A
(zh)
|
2019-12-30 |
2022-10-25 |
德西费拉制药有限责任公司 |
1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
|
AU2020419197B2
(en)
|
2019-12-30 |
2023-08-31 |
Deciphera Pharmaceuticals, Llc |
Amorphous kinase inhibitor formulations and methods of use thereof
|
JP2023512656A
(ja)
|
2020-01-27 |
2023-03-28 |
ギリアード サイエンシーズ, インコーポレイテッド |
SARS CoV-2感染を治療するための方法
|
US11613553B2
(en)
|
2020-03-12 |
2023-03-28 |
Gilead Sciences, Inc. |
Methods of preparing 1′-cyano nucleosides
|
US11802125B2
(en)
|
2020-03-16 |
2023-10-31 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocyclic compounds as antiviral agents
|
CN115605493A
(zh)
|
2020-03-20 |
2023-01-13 |
吉利德科学公司(Us) |
4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
|
EP4132651A1
(en)
|
2020-04-06 |
2023-02-15 |
Gilead Sciences, Inc. |
Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
|
AR121905A1
(es)
|
2020-04-22 |
2022-07-20 |
Assembly Biosciences Inc |
Compuestos de carboxamida heteroarilo de 5 miembros para el tratamiento del hbv
|
WO2021216660A1
(en)
|
2020-04-22 |
2021-10-28 |
Assembly Biosciences, Inc. |
5-membered heteroaryl carboxamide compounds for treatment of hbv
|
WO2021216661A1
(en)
|
2020-04-22 |
2021-10-28 |
Assembly Biosciences, Inc. |
Pyrazole carboxamide compounds for treatment of hbv
|
WO2021216642A1
(en)
|
2020-04-22 |
2021-10-28 |
Assembly Biosciences, Inc. |
Pyrazole carboxamide compounds for treatment of hbv
|
TW202203941A
(zh)
|
2020-05-29 |
2022-02-01 |
美商基利科學股份有限公司 |
瑞德西韋之治療方法
|
US11939347B2
(en)
|
2020-06-24 |
2024-03-26 |
Gilead Sciences, Inc. |
1′-cyano nucleoside analogs and uses thereof
|
WO2022031894A1
(en)
|
2020-08-07 |
2022-02-10 |
Gilead Sciences, Inc. |
Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
|
IL300412A
(en)
|
2020-08-24 |
2023-04-01 |
Gilead Sciences Inc |
Phospholipid compounds and their uses
|
MX2023002195A
(es)
|
2020-08-27 |
2023-03-03 |
Gilead Sciences Inc |
Compuestos y metodos para el tratamiento de infecciones virales.
|
WO2022052923A1
(zh)
*
|
2020-09-08 |
2022-03-17 |
和博医药有限公司 |
二氢嘧啶类化合物、其应用
|
TW202344257A
(zh)
|
2020-10-16 |
2023-11-16 |
美商基利科學股份有限公司 |
磷脂化合物及其用途
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
WO2022166923A1
(zh)
*
|
2021-02-05 |
2022-08-11 |
和博医药有限公司 |
苯基二氢嘧啶类化合物及其应用
|
KR20240006683A
(ko)
|
2021-05-13 |
2024-01-15 |
길리애드 사이언시즈, 인코포레이티드 |
TLR8 조절 화합물과 항-HBV siRNA 치료제의 조합물
|
WO2022251318A1
(en)
|
2021-05-26 |
2022-12-01 |
Gilead Sciences, Inc. |
Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
|
CA3222595A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
US20230046340A1
(en)
|
2021-06-23 |
2023-02-16 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
WO2022271684A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
CA3220923A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
CA3228162A1
(en)
|
2021-08-18 |
2023-02-23 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
WO2023069545A1
(en)
|
2021-10-20 |
2023-04-27 |
Assembly Biosciences, Inc. |
5-membered heteroaryl carboxamide compounds for treatment of hbv
|
WO2023069547A1
(en)
|
2021-10-20 |
2023-04-27 |
Assembly Biosciences, Inc. |
5-membered heteroaryl carboxamide compounds for treatment of hbv
|
WO2023069544A1
(en)
|
2021-10-20 |
2023-04-27 |
Assembly Biosciences, Inc. |
5-membered heteroaryl carboxamide compounds for treatment of hbv
|
WO2023164181A1
(en)
|
2022-02-25 |
2023-08-31 |
Assembly Biosciences, Inc. |
Benzothia(dia)zepine compounds for treatment of hbv and hdv
|
WO2023164179A1
(en)
|
2022-02-25 |
2023-08-31 |
Assembly Biosciences, Inc. |
Benzothia(dia)zepine compounds for treatment of hbv and hdv
|
WO2023164186A1
(en)
|
2022-02-25 |
2023-08-31 |
Assembly Biosciences, Inc. |
Benzothia(dia)zepine compounds for treatment of hbv and hdv
|
WO2023164183A1
(en)
|
2022-02-25 |
2023-08-31 |
Assembly Biosciences, Inc. |
Benzothia(dia)zepine compounds for treatment of hbv and hdv
|
US20230295172A1
(en)
|
2022-03-02 |
2023-09-21 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
US20230322813A1
(en)
|
2022-03-02 |
2023-10-12 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
WO2023168194A1
(en)
|
2022-03-03 |
2023-09-07 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
US20230382940A1
(en)
|
2022-03-03 |
2023-11-30 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
WO2023239665A1
(en)
|
2022-06-06 |
2023-12-14 |
Gilead Sciences, Inc. |
Methods for treatment of viral infections including sars-cov-2
|
WO2024006376A1
(en)
|
2022-06-29 |
2024-01-04 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
WO2024006461A1
(en)
|
2022-06-30 |
2024-01-04 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|